Oxurion Extends Financing Agreement With Atlas

Oxurion NV, a biopharmaceutical company in Leuven, Belgium, announced an extension of its financing program through a third amendment with Atlas Special Opportunities, LLC. This amendment, now assigned to Atlas Special Opportunities II, LLC, allows Oxurion to continue issuing convertible bonds under adjusted conditions until December 2025, with the program lasting until March 2, 2026.

The bond maturity for issued and future bonds is set at 60 months from issuance, ensuring uniformity. The agreement requires a minimum market cap of EUR 500,000 for bond issuance and a provision for partial drawdowns if the cap temporarily falls to EUR 250,000.

Liquidity is crucial, with a minimum trading volume of EUR 1.2 million required over 22 days, allowing partial drawdowns if liquidity drops. Oxurion's monthly bond issuance is set at EUR 300,000, potentially increasing by EUR 100,000 based on subscriber approval.